Foetal Metformin Exposure, Childhood Adiposity and Future Cardiovascular Risk: Can We Connect the Dots?
Abstract
The prevalence of gestational diabetes (GD) and pre-existing diabetes during pregnancy has been increasing. Insulin is the accepted pharmacological treatment for hyperglycaemia in pregnancy. Metformin has emerged as a promising alternative or adjunct due to its ease of use, lower cost and reduced risk of hypoglycaemia. Beyond GD, metformin also shows potential utility in early GD and polycystic ovary syndrome. Current evidence suggests that using metformin in these settings does not raise short-term safety concerns. Some studies show that metformin reduces maternal weight gain and lowers the incidence of large-for-gestational-age (LGA) infants. Despite these benefits, the broader adoption of metformin is limited by concerns about its ability to cross the placenta, resulting in foetal concentrations comparable to maternal levels. In utero exposure to metformin has been shown to induce mitochondrial and epigenetic alterations in animal and ex vitro studies. These changes have been linked to childhood obesity, altered adiposity markers and future cardiovascular disease (CVD) risk. Both LGA and small-for-gestational-age (SGA) neonates have an increased risk of future CVD. Metformin may offer protection by reducing the incidence of LGA births; however, an increase in SGA rates, reported in some studies, could offset this potential benefit. SGA infants who experience rapid catch-up growth are particularly vulnerable. It remains unclear whether the altered growth trajectory in…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.